Chokri Ben Lamine: No Routine VTE Prophylaxis for Chronically Bedridden Patients at Home
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Short answer (guideline-based):
No routine VTE prophylaxis for chronically bedridden patients at home.
Guideline Position
American College of Chest Physicians (CHEST Guidelines)
Do NOT recommend pharmacologic prophylaxis for:
- Chronically immobilized patients
- Nursing home residents
- Home-bound patients without acute illness
Rationale:
- Lower VTE incidence vs hospitalized patients
- Higher bleeding risk outweighs benefit
American Society of Hematology (ASH 2018/2021 VTE Guidelines)
Suggest against routine prophylaxis in:
- Long-term immobile patients at home
- Unless additional strong transient risk factors present
When to consider prophylaxis (exception cases)
Only if high-risk transient state, e.g.:
- Recent hospitalization (≤45–90 days)
- Active cancer (especially + chemo)
- Prior VTE
- Acute infection/inflammation
- Marked reduced mobility with additional risk (improve score high)
In such cases short-term prophylaxis may be considered (case-by-case)
Extended prophylaxis trials (important nuance)
- MAGELLAN trial
- APEX trial
- MARINER trial
Show benefit in selected high-risk recently hospitalized patients, not applicable to stable chronically bedridden home patients
Practical Hematology Take
Bedridden alone isn’t indication
Always balance:
VTE risk vs bleeding risk
Focus on:
- Hydration
- Mobilization if possible
- Reassess if clinical status changes
Key References
- Kahn SR et al. CHEST Guideline (2012, updated concepts)
- Spyropoulos AC et al., MARINER Trial (NEJM 2018)
- Cohen AT et al., MAGELLAN Trial (NEJM 2013)
One-line clinical answer
No routine pharmacologic VTE prophylaxis for chronically bedridden patients at home unless additional high-risk transient factors are present.”
Stay updated with Hemostasis Today.
-
Jul 2, 2026, 11:52Praveen Kumar Tirlangi: A New Mechanism of Bleeding in Kyasanur Forest Disease
-
Jul 2, 2026, 11:17Heghine Khachatryan: Novel Biomarkers for Cancer-Associated Thrombosis
-
Jul 2, 2026, 11:17Neeraj Jain: Maharashtra Is Setting the Pace for Integrated Hemoglobinopathy Care
-
Jul 2, 2026, 11:11Safaa Hilal: Improving Postpartum Hemorrhage Outcomes Through Early Warning Scores
-
Jul 2, 2026, 11:10Maria Khan Junaidi: How Age Influences Intracerebral Hemorrhage Outcomes
-
Jul 2, 2026, 10:51Faces of Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jul 2, 2026, 10:44Priya Sriskandarajah: Understanding Anemia of Chronic Disease in Clinical Practice
-
Jul 2, 2026, 10:42Flora Peyvandi: Germline-Targeting Vaccines for HIV
-
Jul 2, 2026, 10:29Nisar Ahmed: The Evolution of Anticoagulation Therapy